They Lost Weight with Compounded GLP-1s. New FDA Rule May Change That

A new rule from the FDA is set to impact the availability of compounded weight loss drugs containing semaglutide, potentially affecting people like Bailey Fields and Todd Kennedy who rely on these medications for affordable weight management solutions.

Bailey Fields and Todd Kennedy, both struggling with weight management for years, found success last summer with compounded weight loss drugs containing semaglutide. These medications were affordable, costing Bailey $199 a month and Todd $165 a month, helping them lose significant weight.

However, upcoming restrictions from the FDA will prohibit the sale of these compounded drugs, posing challenges for those who depend on them. This change follows a ban on compounded tirzepatide medications that took effect in March.

To address the potential gap in access to affordable weight loss medications, pharmaceutical companies like Novo Nordisk and Eli Lilly have introduced discounts for their brand-name drugs Zepbound and Wegovy. Despite these efforts, individuals like Bailey and Todd are unsure if they can afford the pricier alternatives.

Their concerns extend to the possibility of weight regain without access to these medications, as they have struggled with other weight loss methods in the past. Both emphasize the importance of having a variety of options available for weight management, believing that taking away effective tools like compounded drugs is not in the best interest of consumers.

As the FDA continues to navigate the regulation of compounded weight loss drugs, individuals like Bailey and Todd hope for solutions that prioritize affordability and effectiveness in the fight against obesity and related health concerns.